0.462
0.46%
-0.002
Unicycive Therapeutics Inc stock is traded at $0.462, with a volume of 936.41K.
It is down -0.46% in the last 24 hours and up +6.74% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
See More
Previous Close:
$0.46
Open:
$0.4711
24h Volume:
936.41K
Relative Volume:
0.53
Market Cap:
$43.41M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-0.2333
EPS:
-1.98
Net Cash Flow:
$-18.30M
1W Performance:
-14.12%
1M Performance:
+6.74%
6M Performance:
-55.97%
1Y Performance:
-8.91%
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
UNCY | 0.4621 | 43.41M | 0 | -30.54M | -18.30M | -1.98 |
VRTX | 467.19 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.91 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 566.22 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.54 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.55 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Logos Global Management LP Adjusts Stake in Unicycive Therapeuti - GuruFocus.com
RA Capital Management's Strategic Acquisition of Unicycive Thera - GuruFocus.com
Great Point Partners LLC's Strategic Investment in Unicycive The - GuruFocus.com
Walleye Capital LLC Acquires New Stake in Unicycive Therapeutics Inc - GuruFocus.com
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Unicycive's OLC Drug Gets FDA Review Date, Reports Strong Q3 Pipeline Progress | UNCY Stock News - StockTitan
USFDA accepts Shilpa Medicare CDMO partner Unicycive NDA for Oxylanthanum Carbonate - Medical Dialogues
Unicycive Therapeutics (NASDAQ:UNCY) Given Buy Rating at HC Wainwright - MarketBeat
Unicycive shares hold as FDA accepts NDA for kidney treatment By Investing.com - Investing.com UK
Shilpa Medicare update on its CDMO partnerUnicycive Therapeutics - Business Standard
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - Marketscreener.com
Unicycive eyes June FDA verdict for hyperphosphataemia drug - pharmaphorum
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia - MarketWatch
Unicycive Therapeutics Announces U.S. FDA Acceptance of the - GlobeNewswire
Unicycive's Kidney Disease Drug Gets FDA Review Date, Aims for 2025 Launch | UNCY Stock News - StockTitan
Thinking about buying stock in Beyondspring, LAVA Therapeutics, - GuruFocus.com
Unicycive Therapeutics Delivers Multiple Poster - GlobeNewswire
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - StockTitan
Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - StockTitan
This trade activity should not be overlooked: Unicycive Therapeutics Inc (UNCY) - SETE News
Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near? - Simply Wall St
A year in review: Unicycive Therapeutics Inc (UNCY)’s performance in the last year - US Post News
Unicycive to present kidney disease therapies at ASN Kidney Week - Investing.com
Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.37, Up 3.12 - The Dwinnex
Unicycive to present kidney disease therapies at ASN Kidney Week By Investing.com - Investing.com South Africa
UNCYUnicycive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Unicycive Therapeutics Announces Late-Breaker Poster - GlobeNewswire
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance
Unicycive Therapeutics (UNCY) Price Target Increased by 21.14% to 5.41 - MSN
Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc - Yahoo Finance
Octagon Capital Advisors LP Acquires New Stake in Unicycive Ther - GuruFocus.com
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
Unicycive reports successful phase 1 kidney drug trial - Investing.com
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - The Manila Times
Unicycive reports successful phase 1 kidney drug trial By Investing.com - Investing.com UK
Unicycive Therapeutics Inc (UNCY) is looking forward to a strong quarter - SETE News
UNCY’s earnings forecast for the current quarter - US Post News
Ratio Analysis: Unpacking Unicycive Therapeutics Inc (UNCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Unicycive Therapeutics Inc: Weathering Stock Market Storms with 35.62M Market Cap - The InvestChronicle
Get in on Unicycive Therapeutics Inc’s (UNCY) buy-in window today! - SETE News
Unicycive Therapeutics' SWOT analysis: stock potential in kidney disease market - Investing.com
Was anything positive for Unicycive Therapeutics Inc (UNCY) stock last session? - US Post News
What is Unicycive Therapeutics Inc (UNCY) Stock Return on Shareholders’ Capital? - SETE News
Market Recap Check: Unicycive Therapeutics Inc (UNCY)’s Positive Finish at 0.44, Up/Down 2.82 - The Dwinnex
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - ForexTV.com
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor - EIN News
Unicycive Therapeutics Inc (UNCY) deserves closer scrutiny - US Post News
Unicycive Therapeutics (NASDAQ:UNCY) and Aprea Therapeutics (NASDAQ:APRE) Head to Head Comparison - Defense World
Take off with Unicycive Therapeutics Inc (UNCY): Get ready for trading - SETE News
Examining Unicycive Therapeutics Inc (UNCY) more closely is necessary - US Post News
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):